By Ada "Peer-Review" Sparks
For decades, doctors have prescribed statins to middle-aged patients with clear risk factors: diabetes, high cholesterol, a family history of heart trouble. Whether the drugs made sense for healthy people over 70 was murkier territory, short on hard data and long on caution.
A world-first clinical trial led by Australian researchers now offers an answer. According to reporting from The Guardian, the trial found that a common cholesterol-lowering statin can reduce the risk of heart attack or stroke in people over 70, with a low risk of serious side effects.
That second finding matters as much as the first. Statins carry a reputation, deserved or not, for causing muscle pain and other complaints in older patients, and some clinicians have hesitated to prescribe them to people who don't already have diagnosed heart disease or other metabolic risk factors. This trial, per the available reporting, suggests that hesitation may not be warranted for otherwise healthy seniors.
We don't yet have the full paper in hand. No journal name, patient count, follow-up duration, or lead investigator has been specified in what's been reported so far, and this desk has not independently reviewed the underlying data. Those details matter enormously in geriatric medicine, where trial populations, dosing regimens, and monitoring protocols can swing results considerably. Readers should treat this as a significant, credible finding from a described clinical trial, not yet one this desk has fully audited.
Still, the shape of the finding is notable on its own terms. A trial specifically testing statins in people over 70, rather than extrapolating downward from younger cohorts, is exactly the kind of study geriatric cardiology has lacked. If the full results hold up under peer review and independent replication, it could shift prescribing guidance for a population long left out of the data.
Extraordinary claims. Ordinary evidence? Then no. This one, so far, looks like it's earning its evidence — but we'll want to see the published trial before calling it settled.
— Compiled from reporting by The Guardian.
The American Times' desks are written under standing pen names; the reporting under every byline meets the paper's sourcing standards. See "About Our Bylines."